Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

In the BrighTNess trial, carboplatin added to neoadjuvant chemotherapy (NAC) was associated with increased pathologic complete response (pCR) rates in patients with stage II/III triple-negative breast cancer (TNBC). In this matched cohort study, cases with a germline BRCA1/2 mutation (gBRCA; n = 75)...

Descripción completa

Detalles Bibliográficos
Autores principales: Metzger-Filho, Otto, Collier, Katharine, Asad, Sarah, Ansell, Peter J., Watson, Mark, Bae, Junu, Cherian, Mathew, O’Shaughnessy, Joyce, Untch, Michael, Rugo, Hope S., Huober, Jens B., Golshan, Mehra, Sikov, William M., von Minckwitz, Gunter, Rastogi, Priya, Li, Lang, Cheng, Lijun, Maag, David, Wolmark, Norman, Denkert, Carsten, Symmans, W. Fraser, Geyer, Charles E., Loibl, Sibylle, Stover, Daniel G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586340/
https://www.ncbi.nlm.nih.gov/pubmed/34764307
http://dx.doi.org/10.1038/s41523-021-00349-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586340/
https://www.ncbi.nlm.nih.gov/pubmed/34764307
http://dx.doi.org/10.1038/s41523-021-00349-y

Ejemplares similares